Jaakko Nevalainen

Jaakko Nevalainen

Auto-generated profile, based on publicly available information

Jaakko Nevalainen

Faculty of Social Sciences, Tampere University, Tampere, Finland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2009 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
MEMaijaliisa Erkkola
Maijaliisa Erkkola
MKM. Kaila
M. Kaila
BNB. I. Nwaru
B. I. Nwaru
CKC. Kronberg‐Kippilä
C. Kronberg‐Kippilä
SAS. Ahonen
S. Ahonen
SVSuvi M. Virtanen
Suvi M. Virtanen

1 August 2002 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TPTrevor Powles
Trevor Powles
SPSandy Paterson
Sandy Paterson
JKJohn A. Kanis
John A. Kanis
EMEugene McCloskey
Eugene McCloskey
SASue Ashley
Sue Ashley
LPLiisa Pylkkänen
Liisa Pylkkänen
PURPOSE: The development of bone metastases depends on tumor-induced osteoclastic resorption of bone, which may be inhibited by the antiosteolytic bisphosphonate clodronate. Given to patients with primary breast cancer, clodronate might reduce the subsequent incidence of bone metastases. PATIENTS AND METHODS: This double-blind, multicenter trial accrued 1,069 assessable patients with operable breast cancer between 1989 and 1995. All patients received surgery, radiotherapy, chemotherapy, and tamoxifen as required. Patients were randomized to receive oral clodronate 1,600 mg/d or a placebo for 2 years starting within 6 months of primary treatment. The primary end point was relapse in bone, analyzed on an intent-to-treat basis, during the medication period and during the total follow-up period (median follow-up, 2,007 days). Secondary end points were relapse in other sites, mortality, and toxicity. RESULTS: During the total follow-up period, there was a nonsignificant reduction in occurrence of bone metastases (clodronate, n = 63; placebo, n = 80; hazards ratio [HR], 0.77; 95% confidence interval [CI], 0.56 to 1.08; P = .127). During the medication period there was a significant reduction in the occurrence of bone metastases (clodronate, n = 12; placebo, n = 28; HR, 0.44; 95% CI, 0.22 to 0.86; P = .016). The occurrence of nonosseous metastases was similar (clodronate, n = 112; placebo, n = 128; P = .257), but there was a significant reduction in mortality (clodronate, n = 98; placebo, n = 129; P = .047) during the total follow-up period. CONCLUSION: Clodronate, given to patients with primary operable breast cancer, may reduce the occurrence of bone metastases, although this reduction was only significant during this medication period. There was a significant reduction in mortality.

1 May 2017 in JACC
Verified
Journal Article
Closed access
SRSuvi P. Rovio
Suvi P. Rovio
KPKatja Pahkala
Katja Pahkala
JNJaakko Nevalainen
Jaakko Nevalainen
MJMarkus Juonala
Markus Juonala
PSPia Salo
Pia Salo
OROlli T. Raitakari
Olli T. Raitakari

20 January 2021 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
THTopi Hovinen
Topi Hovinen
LKLiisa Korkalo
Liisa Korkalo
RFRiitta Freese
Riitta Freese
ESEssi Skaffari
Essi Skaffari
PIPirjo Isohanni
Pirjo Isohanni
ASAnu Suomalainen
Anu Suomalainen
Vegan diets are gaining popularity, also in families with young children. However, the effects of strict plant‐based diets on metabolism and micronutrient status of children are unknown. We recruited 40 Finnish children with a median age 3.5 years—vegans, vegetarians, or omnivores from same daycare centers—for a cross‐sectional study. They enjoyed nutritionist‐planned vegan or omnivore meals in daycare, and the full diets were analyzed with questionnaires and food records. Detailed analysis of serum metabolomics and biomarkers indicated vitamin A insufficiency and border‐line sufficient vitamin D in all vegan participants. Their serum total, HDL and LDL cholesterol, essential amino acid, and docosahexaenoic n‐3 fatty acid (DHA) levels were markedly low and primary bile acid biosynthesis, and phospholipid balance was distinct from omnivores. Possible combination of low vitamin A and DHA status raise concern for their visual health. Our evidence indicates that (i) vitamin A and D status of vegan children requires special attention; (ii) dietary recommendations for children cannot be extrapolated from adult vegan studies; and (iii) longitudinal studies on infant‐onset vegan diets are warranted.

1 February 2012 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
SVSuvi M. Virtanen
Suvi M. Virtanen
JNJaakko Nevalainen
Jaakko Nevalainen
CKCarina Kronberg-Kippilä
Carina Kronberg-Kippilä
SASuvi Ahonen
Suvi Ahonen
HTHeli Tapanainen
Heli Tapanainen
MKMikael Knip
Mikael Knip
Background: Evidence for the role of food consumption during childhood in the development of β cell autoimmunity is scarce and fragmentary.Objective:

20 January 2015 in Circulation
Verified
Journal Article
Open access
PDF file
LPLaura Pulkki-Råback
Laura Pulkki-Råback
MEMarko Elovainio
Marko Elovainio
CHChristian Hakulinen
Christian Hakulinen
JLJari Lipsanen
Jari Lipsanen
Mirka HintsanenMirka Hintsanen
Mirka Hintsanen
LKLiisa Keltikangas-Järvinen
Liisa Keltikangas-Järvinen
Background—: The American Heart Association has defined a new metric of ideal cardiovascular health as part of its 2020 Impact Goals. We examined whether psychosocial factors in youth predict ideal cardiovascular health in adulthood. Methods and Results—: Participants were 477 men and 612 women from the nationwide Cardiovascular Risk in Young Finns Study. Psychosocial factors were measured from cohorts 3 to 18 years of age at the baseline of the study, and ideal cardiovascular health was examined 27 years later in adulthood. The summary measure of psychosocial factors in youth comprised socioeconomic factors, emotional factors, parental health behaviors, stressful events, self-regulation of the child, and social adjustment of the child. There was a positive association between a higher number of favorable psychosocial factors in youth and greater ideal cardiovascular health index in adulthood (β=0.16; P <0.001) that persisted after adjustment for age, sex, medication use, and cardiovascular risk factors in childhood (β=0.15; P <0.001). The association was monotonic, suggesting that each increment in favorable psychosocial factors was associated with improvement in cardiovascular health. Of the specific psychosocial factors, a favorable socioeconomic environment (β=0.12; P <0.001) and participants’ self-regulatory behavior (β=0.07; P =0.004) were the strongest predictors of ideal cardiovascular health in adulthood. Conclusions—: The findings suggest a dose-response association between favorable psychosocial factors in youth and cardiovascular health in adulthood, as defined by the American Heart Association metrics. The effect seems to persist throughout the range of cardiovascular health, potentially shifting the population distribution of cardiovascular health rather than simply having effects in a high-risk population.